CNS-reactive B cells in the blood are biomarkers for therapeutic responsiveness and disease activity in Lemtrada-treated MS patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015528

Enrollment

Registered

2018-09-14

Start date

2018-11-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35

Interventions

Group 1: Measurement of CNS-reactive B cells in the blood of patients with relapsing-remitting multiple sclerosis (RRMS) using ELISPOT. Alle patients will be treated with Lemtrada (Alemtuzumab).

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: RRMS, treatment with Lemtrada (Alemtuzumab)

Exclusion criteria

Exclusion criteria: Lack of compliance

Design outcomes

Primary

Measure	Time frame
Number of CNS-reactive B cells in the blood	—

Secondary

Measure	Time frame
Treatment response to Lemtrada (Alemtuzumab)	—

Countries

Germany

Contacts

Public ContactStefanie Kürten

Institut für Neuroanatomie

stefanie.kuerten@uni-bonn.de0228-73-2642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 9, 2026